Newsroom
Sorted by: Latest
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: MACQUARIE BANK LIMITED EUR 500,000,000.00 MATURING: 19-Nov-2027 ISIN: XS3233868119 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 19-Nov-2026 TO 19-Feb-2027 HAS BEEN FIXED AT 3.13 PCT DAY BASIS: ACTUAL/360 INTEREST PAYABLE VALUE 19-Feb-2027 WILL AMOUNT TO: EUR 4,004,555.56 PER EUR 500,000,000.00 DENOMINATION ...
-
Louisiana Appeals Court Upholds Millions in Damages in Mesothelioma Case Against Johnson & Johnson
DALLAS--(BUSINESS WIRE)--An appeals court in Louisiana has upheld a multimillion verdict against Johnson & Johnson, in which a jury found that talc in its baby powder caused a New Orlean's woman's mesothelioma and death.In a Nov. 16 ruling, Louisiana's Fourth Circuit Court of Appeal affirmed a trial court's decision to increase damages awarded to the family of Jeannine Henderson. National plaintiffs trial firm Dean Omar Branham Shirley, LLP (DOBS) represented the Henderson family as well as...
-
Oldcastle BuildingEnvelope Introduces a New StormMax® Hurricane-Impact System
DALLAS--(BUSINESS WIRE)--For coastal construction, hurricane-impact performance is only part of the challenge. Architects and glaziers also need façade systems that can move efficiently from specification and fabrication through installation and building dry-in. To address both, Oldcastle BuildingEnvelope (OBE), a leading supplier of architectural glass, metal, and hardware, introduces the Reliance™ StormMax® Unit Wall curtain wall system, a new High Velocity Hurricane Zone (HVHZ)-approved syst...
-
Rosen Law Firm Encourages SK hynix Inc. Investors to Inquire About Securities Class Action Investigation - SKHY
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of SK hynix Inc. (NASDAQ: SKHY) resulting from allegations that SK hynix may have issued materially misleading business information to the investing public. So What: If you purchased SK hynix securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The...
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: LACE FUNDING 2025-1 PLC GBP 6,550,000.00 MATURING: 21-Nov-2074 ISIN: XS2982091444 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 21-Aug-2026 TO 23-Nov-2026 HAS BEEN FIXED AT 0.00 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 23-Nov-2026 WILL AMOUNT TO: GBP .0 PER GBP 1,262,288.15 DENOMINATION ...
-
ASSA ABLOY Global Solutions Appoints Nicolas Aznar Senior Vice President & Head of Key and Asset Management
OLNEY, England--(BUSINESS WIRE)--ASSA ABLOY Global Solutions today announced the appointment of Nicolas Aznar as Senior Vice President & Head of Key and Asset Management, overseeing the Traka and KEYper businesses. His appointment took effect on 1 November 2026.In his new role, Aznar leads the Key and Asset Management business area within ASSA ABLOY Global Solutions. Traka and KEYper are the Key and Asset Management brands of ASSA ABLOY Global Solutions, providing technologies designed to he...
-
Apptegy Earns Dual Honors with the 2027 GovWire 150 and the 2027 GSV 150
LITTLE ROCK, Ark.--(BUSINESS WIRE)--Apptegy is recognized as one of 50 education honorees on the inaugural GovWire 150 and as a company on the GSV 150, presented by NU Advisory Partners....
-
Riassunto: Povofortay® (povorcitinib) approvato in Europa come il primo trattamento orale in monodose giornaliera per pazienti adulti con idrosadenite suppurativa da moderata a grave
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) oggi ha annunciato che la Commissione Europea (CE) ha approvato Povofortay ® (povorcitinib) 45 mg e 75 mg per il trattamento di pazienti adulti idonei affetti da idrosadenite suppurativa (HS) da moderata a grave. “L'approvazione di Povofortay da parte della Commissione Europea segna una tappa importante per Incyte, in quanto promuove un fattore chiave di crescita per la nostra azienda e offre una nuova opzione terapeutica alle persone che...
-
Resumen: Povofortay® (povorcitinib), aprobado en Europa como el primer tratamiento oral que se administra una vez al día para adultos con hidradenitis supurativa de moderada a grave
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) anunció hoy que la Comisión Europea (CE) ha aprobado Povofortay® (povorcitinib) en dosis de 45 mg y 75 mg para el tratamiento de adultos con hidradenitis supurativa (HS) de moderada a grave que cumplan los criterios de elegibilidad. «La aprobación de Povofortay por parte de la Comisión Europea supone un hito importante para Incyte: impulsa uno de los principales motores de crecimiento de nuestro negocio y ofrece una nueva opción terap...
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: Macquarie Group Limited USD 23,000,000.00 MATURING: 24-Aug-2027 ISIN: XS2525178047 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 24-Aug-2026 TO 24-Nov-2026 HAS BEEN FIXED AT 5.85 PCT DAY BASIS: ACTUAL/360 INTEREST PAYABLE VALUE 24-Nov-2026 WILL AMOUNT TO: USD 343,770.06 PER USD 23,000,000.00 DENOMINATION ...